[Click eStock] "Green Cross Wellbeing, Toxin and Export Added to Steady Business"

On the 14th, DS Investment & Securities analyzed that Green Cross Wellbeing's acquisition of domestic toxin company Inibio has "increased its investment attractiveness." They maintained a 'Buy' rating with a target price of 14,000 KRW.

Green Cross Wellbeing, which operates in the nutritional injection and health functional food business, announced on the 12th that it acquired a 21.4% stake in Inibio, which produces the toxin product 'Iniboju,' becoming the largest shareholder.

Iniboju is currently sold mainly in Southeast Asia and CIS countries. Approvals are expected this year in Thailand, Brazil, and Taiwan. Next year, they plan to complete the approval application and obtain sales authorization in China. Green Cross Wellbeing expects Iniboju sales to increase from 26 billion KRW this year to 42 billion KRW next year.

Green Cross Wellbeing's existing businesses, including the placental injection 'Linec' and the health functional food sector, are also progressing smoothly. Linec is undergoing additional intravenous administration methods, formulation changes, and expanding its client base. The health functional food B2C sector is also expected to turn profitable this year.

Analyst An Juwon stated, "With stable core businesses complemented by growth points in 'toxin' and 'exports,' the investment attractiveness has further increased."

According to Green Cross Wellbeing's consolidated financial statements announced at the end of last month, last year's performance recorded sales of 133.8 billion KRW and an operating profit of 13 billion KRW.

This content was produced with the assistance of AI translation services.